Growing demand and new regulations have put the onus on plan sponsors to prioritize the need for a comprehensive home infusion strategy.

Accelerating the progress of biosimilars is key to lowering drug costs and improving patient access to potentially life-saving therapies.

Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.

Drug trend, a good annual barometer for plan sponsor who are looking to control traditional and specialty drug costs, can and should be managed to improve medication access. This topic was the foc...

Biosimilars, gene and cell therapies, and cancer drugs are filling the specialty pipeline. Here are some insights for each category to help you stay informed. This topic was the focus of a breakout...

Through secure automation, Accredo is improving the specialty prescribing journey for physicians so patients receive their medication faster.